Spyre Therapeutics, Inc. Insider Trading

SYRE

Last 12 months

Insiders sold $43.3M and bought nothing on the open market.

97% of the selling was scheduled in advance under 10b5-1 plans. Chief Financial Officer Scott L Burrows sold $1.31M on Jun 25, 13% of their stake, outside a plan. The last open-market buy by an executive or director was in Aug 2022.

Net open-market

−$43.3M

0 buys · 30 sales

Under a 10b5-1 plan

97%

of the value sold

Insiders who bought / sold

0 / 6

executives and directors

Last open-market buy

Aug 2022

Aug 25, 2022

Get an email when SYRE's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 1	Heidy King-Jones See Remarks	Sold10b5-1 plan 5 parts	28,933	$91.03 average	$2.63M	91%	Form 4
Oct 1	Cameron Turtle Chief Executive Officer	Sold10b5-1 plan 6 parts	15,000	$92.01 average	$1.38M	2.7%	Form 4
Sep 30 – Oct 1	Scott L Burrows Chief Financial Officer	Sold10b5-1 plan 6 parts	25,000	$90.47 average	$2.26M	24%	Form 4
Sep 1 – 2	Heidy King-Jones See Remarks	Sold10b5-1 plan 5 parts	28,399	$87.35 average	$2.48M	91%	Form 4
Sep 1 – 2	Scott L Burrows Chief Financial Officer	Sold10b5-1 plan 5 parts	25,732	$88.75 average	$2.28M	24%	Form 4
Sep 1	Cameron Turtle Chief Executive Officer	Sold10b5-1 plan 4 parts	15,000	$87.29 average	$1.31M	2.6%	Form 4
Aug 7	Jeffrey W. Albers Director	Sold10b5-1 plan 3 parts	23,000	$104.53 average	$2.4M	71%	Form 4
Aug 3	Scott L Burrows Chief Financial Officer	Sold10b5-1 plan 3 parts	7,500	$95.57 average	717K	7.1%	Form 4
Aug 3	Cameron Turtle Chief Executive Officer	Sold10b5-1 plan 5 parts	15,000	$95.51 average	$1.43M	2.6%	Form 4
Jul 1	Scott L Burrows Chief Financial Officer	Sold10b5-1 plan 2 parts	7,500	$87.74 average	658K	7.1%	Form 4
Jul 1	Sheldon Sloan Chief Medical Officer	Sold10b5-1 plan 2 parts	8,334	$87.70 average	731K	100%	Form 4
Jul 1	Cameron Turtle Chief Executive Officer	Sold10b5-1 plan 3 parts	15,000	$87.69 average	$1.32M	2.5%	Form 4
Jun 25	Scott L Burrows Chief Financial Officer	SoldNo plan 2 parts	15,000	$87.13 average	$1.31M	13%	Form 4
Jun 23	Fairmount Funds Management LLC Large holder	SoldNo plan	4,684,781	$85.31	$400M	85%	Form 4
Jun 22	Michael Thomas Henderson Director	Sold10b5-1 plan	20,000	$100.00	$2M	23%	Form 4
Jun 3	Sheldon Sloan Chief Medical Officer	Sold10b5-1 plan	8,333	$75.00	625K	100%	Form 4
Jun 1	Cameron Turtle Chief Executive Officer	Sold10b5-1 plan 3 parts	15,000	$70.43 average	$1.06M	2.4%	Form 4
Jun 1	Scott L Burrows Chief Financial Officer	Sold10b5-1 plan 3 parts	7,500	$71.06 average	533K	7.1%	Form 4
May 8	Michael Thomas Henderson Director	Sold10b5-1 plan 4 parts	80,000	$74.40 average	$5.95M	47%	Form 4
May 1	Sheldon Sloan Chief Medical Officer	Sold10b5-1 plan 7 parts	78,333	$71.50 average	$5.6M	100%	Form 4
May 1	Scott L Burrows Chief Financial Officer	Sold10b5-1 plan	12,500	$71.37	892K	11%	Form 4
May 1	Cameron Turtle Chief Executive Officer	Sold10b5-1 plan 6 parts	15,000	$71.37 average	$1.07M	2.4%	Form 4
Apr 1	Scott L Burrows Chief Financial Officer	Sold10b5-1 plan 2 parts	7,500	$49.34 average	370K	7.1%	Form 4
Apr 1	Cameron Turtle Chief Executive Officer	Sold10b5-1 plan 2 parts	15,000	$49.33 average	740K	2.3%	Form 4
Apr 1	Sheldon Sloan Chief Medical Officer	Sold10b5-1 plan	7,958	$50.00	398K	100%	Form 4
Mar 3	Scott L Burrows Chief Financial Officer	Sold10b5-1 plan 2 parts	2,500	$40.65 average	102K	2.5%	Form 4
Mar 2	Cameron Turtle Chief Executive Officer	Sold10b5-1 plan 2 parts	15,000	$42.19 average	633K	2.3%	Form 4
Feb 2	Cameron Turtle Chief Executive Officer	Sold10b5-1 plan 2 parts	15,000	$32.80 average	492K	2.2%	Form 4
Jan 2	Cameron Turtle Chief Executive Officer	Sold10b5-1 plan 3 parts	15,000	$30.68 average	460K	2.2%	Form 4
Dec 1, 2025	Cameron Turtle Chief Executive Officer	Sold10b5-1 plan 2 parts	15,000	$29.02 average	435K	2.1%	Form 4
Nov 3, 2025	Cameron Turtle Chief Executive Officer	Sold10b5-1 plan 2 parts	45,000	$23.33 average	$1.05M	6.0%	Form 4
Sep 2, 2025	Scott L Burrows Chief Financial Officer	SoldNo plan	18,428	$16.26	300K	16%	Form 4
Nov 6, 2024	Jeffrey W. Albers Director	Sold10b5-1 plan	6,700	$36.76	246K	20%	Form 4

Oct 110b5-1 plan
Heidy King-Jones
See Remarks · sold 28,933 at avg $91.03
$2.63M
91% of stake
Oct 110b5-1 plan
Cameron Turtle
Chief Executive Officer · sold 15,000 at avg $92.01
$1.38M
2.7% of stake
Sep 30 – Oct 110b5-1 plan
Scott L Burrows
Chief Financial Officer · sold 25,000 at avg $90.47
$2.26M
24% of stake
Sep 1 – 210b5-1 plan
Heidy King-Jones
See Remarks · sold 28,399 at avg $87.35
$2.48M
91% of stake
Sep 1 – 210b5-1 plan
Scott L Burrows
Chief Financial Officer · sold 25,732 at avg $88.75
$2.28M
24% of stake
Sep 110b5-1 plan
Cameron Turtle
Chief Executive Officer · sold 15,000 at avg $87.29
$1.31M
2.6% of stake
Aug 710b5-1 plan
Jeffrey W. Albers
Director · sold 23,000 at avg $104.53
$2.4M
71% of stake
Aug 310b5-1 plan
Scott L Burrows
Chief Financial Officer · sold 7,500 at avg $95.57
717K
7.1% of stake
Aug 310b5-1 plan
Cameron Turtle
Chief Executive Officer · sold 15,000 at avg $95.51
$1.43M
2.6% of stake
Jul 110b5-1 plan
Scott L Burrows
Chief Financial Officer · sold 7,500 at avg $87.74
658K
7.1% of stake
Jul 110b5-1 plan
Sheldon Sloan
Chief Medical Officer · sold 8,334 at avg $87.70
731K
100% of stake
Jul 110b5-1 plan
Cameron Turtle
Chief Executive Officer · sold 15,000 at avg $87.69
$1.32M
2.5% of stake
Jun 25No plan
Scott L Burrows
Chief Financial Officer · sold 15,000 at avg $87.13
$1.31M
13% of stake
Jun 23No plan
Fairmount Funds Management LLC
Large holder · sold 4,684,781 at $85.31
$400M
85% of stake
Jun 2210b5-1 plan
Michael Thomas Henderson
Director · sold 20,000 at $100.00
$2M
23% of stake
Jun 310b5-1 plan
Sheldon Sloan
Chief Medical Officer · sold 8,333 at $75.00
625K
100% of stake
Jun 110b5-1 plan
Cameron Turtle
Chief Executive Officer · sold 15,000 at avg $70.43
$1.06M
2.4% of stake
Jun 110b5-1 plan
Scott L Burrows
Chief Financial Officer · sold 7,500 at avg $71.06
533K
7.1% of stake
May 810b5-1 plan
Michael Thomas Henderson
Director · sold 80,000 at avg $74.40
$5.95M
47% of stake
May 110b5-1 plan
Sheldon Sloan
Chief Medical Officer · sold 78,333 at avg $71.50
$5.6M
100% of stake
May 110b5-1 plan
Scott L Burrows
Chief Financial Officer · sold 12,500 at $71.37
892K
11% of stake
May 110b5-1 plan
Cameron Turtle
Chief Executive Officer · sold 15,000 at avg $71.37
$1.07M
2.4% of stake
Apr 110b5-1 plan
Scott L Burrows
Chief Financial Officer · sold 7,500 at avg $49.34
370K
7.1% of stake
Apr 110b5-1 plan
Cameron Turtle
Chief Executive Officer · sold 15,000 at avg $49.33
740K
2.3% of stake
Apr 110b5-1 plan
Sheldon Sloan
Chief Medical Officer · sold 7,958 at $50.00
398K
100% of stake
Mar 310b5-1 plan
Scott L Burrows
Chief Financial Officer · sold 2,500 at avg $40.65
102K
2.5% of stake
Mar 210b5-1 plan
Cameron Turtle
Chief Executive Officer · sold 15,000 at avg $42.19
633K
2.3% of stake
Feb 210b5-1 plan
Cameron Turtle
Chief Executive Officer · sold 15,000 at avg $32.80
492K
2.2% of stake
Jan 210b5-1 plan
Cameron Turtle
Chief Executive Officer · sold 15,000 at avg $30.68
460K
2.2% of stake
Dec 1, 202510b5-1 plan
Cameron Turtle
Chief Executive Officer · sold 15,000 at avg $29.02
435K
2.1% of stake
Nov 3, 202510b5-1 plan
Cameron Turtle
Chief Executive Officer · sold 45,000 at avg $23.33
$1.05M
6.0% of stake
Sep 2, 2025No plan
Scott L Burrows
Chief Financial Officer · sold 18,428 at $16.26
300K
16% of stake
Nov 6, 202410b5-1 plan
Jeffrey W. Albers
Director · sold 6,700 at $36.76
246K
20% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch SYRE, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with SYRE

CompareIntrinsic value

PCRXPacira BioSciences Inc.

$36.39+0.00%58

HRMYHarmony Biosciences Holdings, Inc.

$38.76+0.44%82

LPCNLipocine Inc.

$1.44-5.26%40

VRTXVertex Pharmaceuticals Incorporated

$558.88+3.50%47

RYTMRhythm Pharmaceuticals Inc.

$92.57-0.54%40

DNTHDianthus Therapeutics Inc.

$82.38-0.39%10

ARVNArvinas Inc.

$7.86-0.51%44

PFEPfizer Inc.

$30.52+1.90%32

Held by ETFs

SYRE is in 74 US ETFs. The largest of them, with SYRE's weight in each:

Spot a number that looks wrong? Check it in SYRE's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SYRE

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.